Latest Insider Transactions at Arcus Biosciences, Inc. (RCUS)
This section provides a real-time view of insider transactions for Arcus Biosciences, Inc. (RCUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arcus Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arcus Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 18
2023
|
Dimitry Sa Nuyten Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,708
-4.8%
|
$74,160
$20.4 P/Share
|
|
Jul 28
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
45,000
-11.79%
|
$900,000
$20.25 P/Share
|
|
Jul 03
2023
|
Alexander Azoy Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,018
-8.07%
|
$20,360
$20.41 P/Share
|
|
Jun 28
2023
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,010,000
+6.38%
|
$19,190,000
$19.26 P/Share
|
|
Jun 22
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,437
-3.16%
|
$236,303
$19.12 P/Share
|
|
Jun 16
2023
|
Juan C. Jaen President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,820
-1.51%
|
$91,580
$19.35 P/Share
|
|
Jun 16
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,563
-3.09%
|
$238,697
$19.35 P/Share
|
|
Jun 16
2023
|
Carolyn C. Tang General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,892
-2.93%
|
$54,948
$19.35 P/Share
|
|
Jun 16
2023
|
Terry J Rosen Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,762
-0.22%
|
$166,478
$19.35 P/Share
|
|
Jun 15
2023
|
Juan C. Jaen President |
SELL
Bona fide gift
|
Direct |
6,000
-1.85%
|
-
|
|
Jun 15
2023
|
Andrew J Perlman Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+24.53%
|
-
|
|
Jun 15
2023
|
Nicole Lambert Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+30.36%
|
-
|
|
Jun 15
2023
|
Patrick Machado Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+28.69%
|
-
|
|
Jun 15
2023
|
Antoni Ribas Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+23.65%
|
-
|
|
Jun 15
2023
|
David L. Lacey Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+12.13%
|
-
|
|
Jun 15
2023
|
Kathryn E Falberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+12.66%
|
-
|
|
Jun 15
2023
|
Kathryn E Falberg Director |
SELL
Bona fide gift
|
Direct |
50,504
-55.74%
|
-
|
|
Jun 15
2023
|
Yasunori Kaneko Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+50.0%
|
-
|
|
Jun 07
2023
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,049
-6.38%
|
$80,980
$20.04 P/Share
|
|
Mar 16
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
8,729
-2.1%
|
$139,664
$16.81 P/Share
|
|
Jan 27
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,600
-0.38%
|
$36,800
$23.52 P/Share
|
|
Jan 26
2023
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
300
-0.07%
|
$6,900
$23.56 P/Share
|
|
Jan 23
2023
|
Dimitry Sa Nuyten Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+30.77%
|
-
|
|
Jan 23
2023
|
Juan C. Jaen President |
BUY
Grant, award, or other acquisition
|
Direct |
45,800
+12.36%
|
-
|
|
Jan 23
2023
|
Jennifer Jarrett Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,800
+9.9%
|
-
|
|
Jan 23
2023
|
Carolyn C. Tang General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+25.85%
|
-
|
|
Jan 23
2023
|
Ii Robert C. Goeltz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+34.89%
|
-
|
|
Jan 23
2023
|
Terry J Rosen Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,700
+18.39%
|
-
|
|
Dec 16
2022
|
Terry J Rosen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,043
-2.57%
|
$391,290
$30.95 P/Share
|
|
Dec 16
2022
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Direct |
4,436
-1.0%
|
$133,080
$30.95 P/Share
|
|
Dec 16
2022
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
16,482
-5.1%
|
$494,460
$30.95 P/Share
|
|
Dec 16
2022
|
Carolyn C. Tang General Counsel |
SELL
Open market or private sale
|
Direct |
2,523
-4.1%
|
$75,690
$30.95 P/Share
|
|
Dec 16
2022
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,453
-8.99%
|
$73,590
$30.95 P/Share
|
|
Sep 16
2022
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,677
-8.83%
|
$329,602
$26.28 P/Share
|
|
Aug 23
2022
|
Dimitry Sa Nuyten Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,500
+50.0%
|
-
|
|
Jun 17
2022
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Direct |
2,537
-0.6%
|
$55,814
$22.0 P/Share
|
|
Jun 17
2022
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,614
-2.67%
|
$145,508
$22.0 P/Share
|
|
Jun 17
2022
|
Terry J Rosen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,613
-1.0%
|
$101,486
$22.0 P/Share
|
|
Jun 17
2022
|
Carolyn C. Tang General Counsel |
SELL
Open market or private sale
|
Direct |
1,522
-3.03%
|
$33,484
$22.0 P/Share
|
|
Jun 16
2022
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Direct |
2,333
-1.09%
|
$46,660
$20.72 P/Share
|
|
Jun 16
2022
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,081
-4.63%
|
$121,620
$20.72 P/Share
|
|
Jun 16
2022
|
Terry J Rosen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,241
-1.79%
|
$84,820
$20.72 P/Share
|
|
Jun 16
2022
|
Carolyn C. Tang General Counsel |
SELL
Open market or private sale
|
Direct |
1,400
-5.22%
|
$28,000
$20.72 P/Share
|
|
Jun 14
2022
|
Kathryn E Falberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,100
+4.33%
|
-
|
|
Jun 14
2022
|
Yasunori Kaneko Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,100
+50.0%
|
-
|
|
Jun 14
2022
|
David L. Lacey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,100
+8.81%
|
-
|
|
Jun 14
2022
|
Nicole Lambert Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,100
+50.0%
|
-
|
|
Jun 14
2022
|
Patrick Machado Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,100
+28.87%
|
-
|
|
Jun 14
2022
|
Andrew J Perlman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,100
+26.93%
|
-
|
|
Jun 14
2022
|
Antoni Ribas Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,100
+21.3%
|
-
|